Umeclidinium

DRUG5 trials

Sponsors

GlaxoSmithKline, Stiefel, a GSK Company

Conditions

HyperhidrosisPulmonary Disease, Chronic Obstructivechronic obstructive airways disease (COPD)

Phase 2

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

CompletedNCT02563899

GlaxoSmithKlineHyperhidrosis

Start: 2015-11-23End: 2016-02-25Updated: 2018-10-11

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

CompletedNCT02673619

Stiefel, a GSK CompanyHyperhidrosis

Start: 2016-03-07End: 2016-12-08Updated: 2018-02-09

Phase 3

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

CompletedNCT02207829

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2014-09-01End: 2015-06-15Updated: 2018-01-24

Phase 4

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02236611

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2014-09-26End: 2015-06-02Updated: 2018-05-02

A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)

Active, not recruitingNL-OMON45687

GlaxoSmithKlinechronic obstructive airways disease (COPD)

Start: 2017-06-16Target: 80Updated: 2024-02-28

Related Papers

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.

2018-05-102 citations

A randomised, open-label study of umeclidinium<i>versus</i>glycopyrronium in patients with COPD

ERJ Open Research2016-04-0113 citations